S. Korean firm seeks FDA nod to test stem cell drug for osteoarthritis

05/8/2013 | BioSpectrum Asia

South Korea's RNL Bio submitted an investigational new drug application to the FDA for RNL-JointStem, its adipose-based stem cell treatment for osteoarthritis. If the application is approved, the firm could begin midstage trials in the U.S. next quarter. RNL-JointStem has been tested in Phase I and II studies approved by Korean regulators.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT